Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine

References

• Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015;15:51–57. doi:10.4110/in.2015.15.2.51.
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19:1597–608. doi:10.1038/nm.3409.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Cooper PD. Carbohydrate-based immune adjuvants. Expert Rev Vaccines. 2011;10:523–37. doi:10.1586/erv.11.30.
   PubMed Web of Science ®Google Scholar
• Rosales-Mendoza S, Salazar-Gonzalez JA, Decker EL, Reski R. Implications of plant glycans in the development of innovative vaccines. Expert Rev Vaccines. 2016;15:915–25. doi:10.1586/14760584.2016.1155987.
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Saade F, Petrovsky N. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine. 2012;30:5373–81. doi:10.1016/j.vaccine.2012.06.021.
   PubMed Web of Science ®Google Scholar
• Cooper PD, Barclay TG, Ginic-Markovic M, Petrovsky N. The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions. Glycobiology. 2013;23:1164–74. doi:10.1093/glycob/cwt053.
   PubMed Web of Science ®Google Scholar
• Bruno de Paula Oliveira Santos B, Trentini MM, Machado RB, Rúbia Nunes Celes M, Kipnis A, Petrovsky N, Junqueira-Kipnis AP. Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection. Hum Vaccin Immunother. 2017;13:2967–76. doi:10.1080/21645515.2017.1368598.
   PubMed Web of Science ®Google Scholar
• Carlson CJ, Kracalik IT, Ross N, Alexander KA, Hugh-Jones ME, Fegan M, Elkin BT, Epp T, Shury TK, Zhang W, et al. The global distribution of Bacillus anthracis and associated anthrax risk to humans, livestock and wildlife. Nat Microbiol. 2019;4:1337–43. doi:10.1038/s41564-019-0435-4.
   PubMed Web of Science ®Google Scholar
• Savransky V, Shearer JD, Gainey MR, Sanford DC, Sivko GS, Stark GV, Li N, Ionin B, Lacy MJ, Skiadopoulos MH. Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate. Vaccine. 2017;35:4952–59. doi:10.1016/j.vaccine.2017.07.076.
   PubMed Web of Science ®Google Scholar
• Verma A, Burns DL. Improving the stability of recombinant anthrax protective antigen vaccine. Vaccine. 2018;36:6379–82. doi:10.1016/j.vaccine.2018.09.012.
   PubMed Web of Science ®Google Scholar
• Majumder S, Das S, Somani VK, Makam SS, Kingston JJ, Bhatnagar R. A bivalent protein r-PAbxpB comprising PA domain IV and exosporium protein BxpB confers protection against B. Anthracis spores and toxin. Front Immunol. 2019;10:498. doi:10.3389/fimmu.2019.00498.
   PubMed Web of Science ®Google Scholar
• Weir GM, MacDonald LD, Rajagopalan R, Sivko GS, Valderas MW, Rayner J, Berger BJ, Sammatur L, Stanford MM. Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge. NPJ Vaccines. 2019;4:6. doi:10.1038/s41541-019-0102-z.
   PubMed Web of Science ®Google Scholar
• Sun Y. Biological activities and potential health benefits of polysaccharides from Poria cocos and their derivatives. Int J Biol Macromol. 2014;68:131–34. doi:10.1016/j.ijbiomac.2014.04.010.
   PubMed Web of Science ®Google Scholar
• Wu Y, Li S, Li H, Ma H, Zhao X, Liu K, Wu J, Liu Y, Shan J, Wang Y. Adjuvant effect of a polysaccharide PCP1-Ⅰ from Poria cocos on HBsAg antigen in mice. J Int Pharm Res. 2016;43:307–13.
   Google Scholar
• Yin Y, Zhang S, Cai C, Zhang J, Dong D, Guo Q, Fu L, Xu J, Chen W. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine. Immunobiology. 2014;219:97–103. doi:10.1016/j.imbio.2013.08.008.
   PubMed Web of Science ®Google Scholar
• Marcus H, Danieli R, Epstein E, Velan B, Shafferman A, Reuveny S. Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect Immun. 2004;72:3471–77. doi:10.1128/IAI.72.6.3471-3477.2004.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yin Y, Wang L, Zhang W, Chen X, Yang X, Xu J, Ma G. Engineering biomaterial-associated complement activation to improve vaccine efficacy. Biomacromolecules. 2013;14:3321–28. doi:10.1021/bm400930k.
   PubMed Web of Science ®Google Scholar
• Tarlinton D, Good-Jacobson K. Diversity among memory B cells: origin, consequences, and utility. Science. 2013;341:1205–11. doi:10.1126/science.1241146.
   PubMed Web of Science ®Google Scholar
• Lewis KL, Reizis B. Dendritic cells: arbiters of immunity and immunological tolerance. Cold Spring Harb Perspect Biol. 2012;4:a007401. doi:10.1101/cshperspect.a007401.
   PubMed Web of Science ®Google Scholar
• Tom JK, Albin TJ, Manna S, Moser BA, Steinhardt RC, Esser-Kahn AP. Applications of immunomodulatory immune synergies to adjuvant discovery and vaccine development. Trends Biotechnol. 2019;37:373–88. doi:10.1016/j.tibtech.2018.10.004.
   PubMed Web of Science ®Google Scholar
• Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37:3167–78. doi:10.1016/j.vaccine.2019.04.055.
   PubMed Web of Science ®Google Scholar
• Sun B, Yu S, Zhao D, Guo S, Wang X, Zhao K. Polysaccharides as vaccine adjuvants. Vaccine. 2018;36:5226–34. doi:10.1016/j.vaccine.2018.07.040.
   PubMed Web of Science ®Google Scholar
• Cordeiro AS, Alonso MJ, de la Fuente M. Nanoengineering of vaccines using natural polysaccharides. Biotechnol Adv. 2015;33:1279–93. doi:10.1016/j.biotechadv.2015.05.010.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zheng X, Cheng N, Gai W, Xue X, Wang Y, Gao Y, Shan J, Yang S, Xia X. Isatis indigotica root polysaccharides as adjuvants for an inactivated rabies virus vaccine. Int J Biol Macromol. 2016;87:7–15. doi:10.1016/j.ijbiomac.2016.02.023.
   PubMed Web of Science ®Google Scholar
• Wu Y, Li S, Li H, Zhao C, Ma H, Zhao X, Wu J, Liu K, Shan J, Wang Y. Effect of a polysaccharide from Poria cocos on humoral response in mice immunized by H1N1 influenza and HBsAg vaccines. Int J Biol Macromol. 2016;91:248–57. doi:10.1016/j.ijbiomac.2016.05.046.
   PubMed Web of Science ®Google Scholar
• Li S, Wang Y, Li H, Jia P, Liu K, Jia Q, Shan J, Ma B. Adjuvant effect of total polysaccharides from Poria cocos on H1N1 influenza and HBsAg antigens. Chin J Pharmacol Toxicol. 2015;29:61–64..
   Google Scholar
• Shan J, Sun G, Ren J, Zhu T, Jia P, Qu W, Li Q, Wu J, Ma H, Wen S, et al. An α-glucan isolated from root of Isatis Indigotica, its structure and adjuvant activity. Glycoconj J. 2014;31:317–26. doi:10.1007/s10719-014-9525-y.
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv. 2013;2013:869718. doi:10.1155/2013/869718.
   PubMedGoogle Scholar
• Liu K, Yin Y, Zhang J, Dong D, Liu J, LI R, Ma H, Shan J, Xu J.  Mechanism of a polysaccharides PCP-I from Poria cocos on enhancing antigen-specific humoral immune response. Lett Biotechnol. 2017;28:249–55.
   Google Scholar
• Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963. doi:10.3389/fimmu.2018.01963.
   PubMed Web of Science ®Google Scholar